Table 2.
League table of the response rate
| hf-tONS-Oz | 1.13 (0.53,2.37) | 1.13 (0.53,2.37) | *9.00 (1.24,65.16) | ||||||||
| 1.13 (0.53,2.37) | lf-tONS-Oz | 1.00 (0.46,2.19) | *8.00 (1.09,58.71) | ||||||||
| 1.13 (0.53,2.37) | 1.00 (0.46,2.19) | af-tONS-Oz | *8.00 (1.09,58.71) | ||||||||
| 2.85 (0.31,26.37) | 2.54 (0.27,23.72) | 2.54 (0.27,23.72) | STS-Afz | *3.15 (1.15,8.69) | |||||||
| 3.00 (0.32,27.77) | 2.67 (0.28,24.98) | 2.67 (0.28,24.98) | 1.05 (0.25,4.42) | PENS-Fp1Fp2 | *3.00 (1.09,8.29) | ||||||
| 3.73 (0.49,28.22) | 3.31 (0.43,25.42) | 3.31 (0.43,25.42) | 1.31 (0.44,3.92) | 1.24 (0.41,3.73) | hf-TMS-F3 | 1.14 (0.80,1.63) | *2.41 (1.58,3.68) | ||||
| 4.13 (0.35,49.06) | 3.67 (0.30,44.08) | 3.67 (0.30,44.08) | 1.45 (0.24,8.74) | 1.38 (0.23,8.33) | 1.11 (0.24,5.19) | a-tDCS-Oz+c-tDCS-Cz | 2.18 (0.49,9.65) | ||||
| 4.26 (0.55,33.26) | 3.79 (0.48,29.95) | 3.79 (0.48,29.95) | 1.49 (0.47,4.73) | 1.42 (0.45,4.51) | 1.14 (0.80,1.63) | 1.03 (0.21,5.05) | single-hf-TMS-F3 | ||||
| 5.06 (0.66,38.91) | 4.50 (0.58,35.04) | 4.50 (0.58,35.04) | 1.77 (0.58,5.47) | 1.69 (0.55,5.21) | 1.36 (0.71,2.59) | 1.23 (0.26,5.87) | 1.19 (0.57,2.48) | sTMS-Oz | *1.78 (1.09,2.90) | ||
| 5.05 (0.66,38.95) | 4.49 (0.58,35.07) | 4.49 (0.58,35.07) | 1.77 (0.57,5.48) | 1.68 (0.54,5.23) | 1.36 (0.70,2.61) | 1.23 (0.26,5.88) | 1.19 (0.56,2.50) | 1.00 (0.50,2.01) | Bi-nVNS | *1.78 (1.08,2.94) | |
| 6.91 (0.93,51.46) | 6.14 (0.81,46.35) | 6.14 (0.81,46.35) | 2.42 (0.83,7.04) | 2.30 (0.79,6.72) | *1.85 (1.08,3.18) | 1.67 (0.36,7.70) | 1.62 (0.85,3.10) | 1.36 (0.75,2.47) | 1.37 (0.75,2.50) | Rt-nVNS | 1.30 (0.93,1.83) |
| *9.00 (1.24,65.16) | *8.00 (1.09,58.71) | *8.00 (1.09,58.71) | *3.15 (1.15,8.69) | *3.00 (1.09,8.29) | *2.41 (1.58,3.68) | 2.18 (0.49,9.65) | *2.11 (1.22,3.67) | *1.78 (1.09,2.90) | *1.78 (1.08,2.94) | 1.30 (0.93,1.83) | Sham/Control |
Pairwise (upper-right portion) and network (lower-left portion) meta-analysis results are presented as estimate effect sizes for the outcome of response rate. Interventions are reported in order of mean ranking of treatment response, and outcomes are expressed as response rate ratio (RR) (95% confidence intervals). For the pairwise meta-analyses, RR of more than 1 indicate that the treatment specified in the row got better response than that specified in the column. For the network meta-analysis (NMA), RR of more than 1 indicate that the treatment specified in the column got better response than that specified in the row. Bold results marked with * indicate statistical significance.
Abbreviation: 95%CI 95% confidence interval, af-tONS-Oz Alternative frequency tONS over Oz, a-tDCS-C3+c-tDCS-Fp2 Anode tDCS over C3 + cathode tDCS over Fp2, a-tDCS-F3+c-tDCS-Fp2 Anode tDCS over F3 + cathode tDCS over Fp2, a-tDCS-Oz+c-tDCS-Cz Anode tDCS over Oz + cathode over Cz, Bi-nVNS Bilateral vagus nerve stimulation, c-tDCS-C4+a-tDCS-arm Cathode tDCS over C4 + anode at left upper arm, c-tDCS-CP4+a-tDCS-arm Cathode tDCS over CP4 + anode at left upper arm, c-tDCS-Oz+a-tCDS-Cz Cathode tDCS over Oz + anode tCDS over Cz, dTMS-F3 Deep TMS-F3, ES Effect size, hf-TMS-C3 High frequency rTMS over C3, hf-TMS-F3 High frequency rTMS over F3, hf-tONS-Oz High frequency tONS over Oz, lf-tONS-Oz Low frequency tONS over Oz, MD Mean difference, NMA Network meta-analysis, nVNS Noninvasive vagus nerve stimulation, PENS percutaneous electrical nerve stimulation, PENS-Fp1Fp2 Percutaneous electrical nerve stimulation over Fp1Fp2, RCT randomized controlled trial, RR Rate ratio, rTMS Repetitive transcranial magnetic stimulation, Rt-nVNS: right vagus nerve stimulation, Sham/Control Sham control or waiting list, single-hf-TMS-F3 Single session high frequency rTMS over F3, SMD Standardized mean difference, sTMS Single-pulse TMS, sTMS-Oz single-pulse TMS over Oz, STS: supraorbital transcutaneous stimulation, STS-Afz Supraorbital transcutaneous stimulator over Afz, SUCRA Surface under the cumulative ranking curve, taVNS Transcutaneous auricular vagus nerve stimulation, tDCS Transcranial direct current stimulation, TMS Transcranial magnetic stimulation, tONS Transcutaneous occipital nerve stimulation